Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is awarding Glyprovac LLC US$467,000 to develop a maternal vaccine that targets Escherichia coli, a bacterial species responsible for a large portion of neonatal sepsis infections.

Dyadic International Inc.'s Dutch subsidiary, Dyadic Nederland BV, has entered into a strategic partnership agreement and collaboration with Rabian BV to develop efficacious, scalable, and affordable rabies prophylactics and vaccines utilizing Dyadic's C1 protein production platform.

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) has awarded US$ 2.2 million to Limmatech Biologics AG to advance the development of its novel vaccine candidate to prevent Neisseria gonorrhoeae infections.

Protein-based virus-like particles (P-VLPs) have emerged as a promising platform for multivalent subunit vaccines.

Vaxxinity Inc. has announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases.

Capricor Therapeutics Inc.'s Stealthx exosome-based multivalent vaccine for the prevention of SARS-CoV-2 has been selected to be part of the U.S. Department of Health and Human Services' Project Nextgen initiative aimed at developing COVID-19 vaccines offering broader and more durable protection.

Reithera Srl, The Ragon Institute of Mass General, MIT and Harvard, and IAVI have established a collaboration to develop a novel HIV vaccine candidate based on gorilla adenoviral vector (GRAd), with funding by the Bill & Melinda Gates Foundation.

Promis Neurosciences Inc. has selected a lead vaccine candidate, PMN-400, against synucleinopathies, including multiple system atrophy, Parkinson’s disease and Lewy body dementia.